In an interview with Targeted Oncology, Jennifer A. Woyach, MD, discussed updated results from the phase 1/2 BRUIN study of pirtobrutinib in chronic lymphocytic leukemia or small lymphocytic lymphoma following treatment with a covalent Bruton tyrosine kinase inhibitor.
In an interview with Targeted Oncology, Daniel Baker, PhD candidate at the University of Pennsylvania, discussed the growing role for CAR T-cell therapies outside of the oncology field.
Andrew Srisuwananukorn, MD, assistant professor at The Ohio State University Comprehensive Cancer Center, discussed the use of a novel artificial intelligence model that aids in the differentiating between prefibrotic primary myelofibrosis and essential thrombocythemia.
In an interview with Targeted Oncology™, Michelle M. Issac, MD, discussed the goals of both palliative care and oncology care professionals as they support patients with cancer.
In an interview with Targeted Oncology, Igor Astsaturov, MD, PhD, discussed what led to the development of LP-184 and explained how the agent will be evaluated moving forward.
In an interview with Targeted Oncology, Yazmin Odia, MD, discussed the 3rd Annual Miami Cancer Institute Oncology Rehabilitation Symposium, including her discussion on incorporating rehabilitation into the course of treatment for patients with brain cancer.
In an interview with Targeted Oncology, Eirwen M. Miller, MD, discussed the dynamic landscape of ovarian cancer treatment.
In an interview with Targeted Oncology, Ryan Carey, MD, and Rob Lee, PhD, discussed the preclinical research and the potential for lidocaine to kill certain cancer cells.
In an interview with Targeted Oncology, Edward B. Garon, MD, MS, discussed the ever-changing treatment landscape for EGFR-mutated lung cancer, as well as the unmet needs and potential next steps for research in this space.
In an interview with Targeted Oncology, Lisa B. Ercolano, MD, discussed the evolving treatment landscape for sarcomas and underscored the pivotal role of molecular profiling, while addressing the need for more efficacious systemic therapies.
Neal Shore, MD, FACS, discussed the phase 3 EMBARK trial and what the FDA approval of enzalutamide means for the prostate cancer treatment landscape.
In an interview with Targeted Oncology, Michael Wang, MD, discussed the rationale of the phase 3 study and how positive results from this trial may further shape the mantle cell lymphoma treatment landscape.
In an interview with Targeted Oncology, City of Hope cancer center’s Marwan Fakih, MD, further discussed the findings from this phase 3 trial and future directions for evaluating this combination.
In an interview with Targeted Oncology, Peter Schmid, FRCP, MD, PhD, discussed the implication of findings from the KEYNOTE-522 trial of the addition of pembrolizumab to neoadjuvant chemotherapy in patients with high-risk triple-negative breast cancer.
In an interview with Targeted Oncology, Joshua Sabari, MD, discussed the rationale of studying LY3537982 in the LOXO-RAS-20001 trial and next steps for the evaluation of the agent.
In an interview, Mwanasha Merrill discussed the implication of findings from a phase 2 trial of pembrolizumab after autologous stem cell transplantation for the treatment of patients with peripheral T-cell lymphoma.
In an interview, Funda Meric-Bernstam, MD, discussed the phase 2 DESTINY-PanTumor02 trial and the data on fam-trastuzumab deruxtecan-nxki for the treatment of patients with HER2-expressing cancers.
In an interview with Targeted Oncology, Joseph M. Scandura, MD, PhD, discussed research on pelabresib for the treatment of patients with myeloproliferative neoplasms.
In an interview with Targeted Oncology, Brian Ramnaraign, MD, further discussed the safety of immune checkpoint inhibitors in patients with genitourinary cancers.
In an interview with Targeted Oncology, Skye Montoya discussed noncovalent Bruton's tyrosine kinase inhibitors and mechanisms of resistance in chronic lymphocytic leukemia.
In an interview with Targeted Oncology, Rachna T. Shroff, MD, MS, FASCO, discussed new systemic therapies that are available or being developed to treat patients with intrahepatic cholangiocarcinoma.
Matthew Powell, MD, discusses next steps and unmet needs following the phase 3 RUBY/ENGOT-EN6 study and the FDA approval of dostarlimab in combination with chemotherapy for the treatment of patients with mismatch repair deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer.
In an interview with Targeted Oncology, Francis P. Worden, MD, discussed data from the COSMIC-311 study which support treatment with cabozantinib for patients with radioiodine-refractory differentiated thyroid cancer.
In an interview with Targeted Oncology, Federico Albrecht, MD, discussed advances to treatments for patients with small cell lung cancer and considerations when treating difficult cases.
In an interview with Targeted Oncology, Yi Lin, MD, PhD, discussed the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel for the treatment of patients with relapsed or refractory multiple myeloma.
In an interview, John Diaz, MD, discusses updates to the cervical cancer treatment landscape and where the field is moving to potentially eradicate this disease in the United States.
In an interview with Targeted Oncology, Dan T. Vogl, MD, MSCE, discussed a phase 1 study which evaluated modakafusp alfa for the treatment of patients with relapsed or refractory multiple myeloma.
In an interview with Targeted Oncology, Rohan Garje, MD, discussed current treatment options for patients with prostate cancer and the role of PARP inhibitors.
In an interview with Targeted Oncology, Heather Wakelee, MD, discussed what community oncologists should know about the newly approved combination of pembrolizumab with platinum-containing chemotherapy as neoadjuvant treatment, and with continuation of pembrolizumab monotherapy as post-surgical adjuvant treatment.
In an interview with Targeted Oncology, Rupesh Kotecha, MD, discusses the background of this phase 1 study and current options for patients with brain metastases.